Long-lived plasma cells in autoimmunity: Lessons from B-cell depleting therapy

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Mahévas, Matthieu ^a,b,c   Michel, Marc ^c   Weill, Jean Claude ^a   Reynaud, Claude Agnès ^a  

^a INSERM   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Autoreactive antibody; BAFF Blys; Belimumab; Plasma cell niche; Rituximab

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; B CELL ACTIVATING FACTOR; CD4 ANTIGEN; CELL CYCLE PROTEIN 6; FLICE INHIBITORY PROTEIN; INTERLEUKIN 6; KRUPPEL LIKE FACTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PROTEIN BCL 2; PROTEIN FOS; RITUXIMAB; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR MAFF; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; HUMAN; HUMORAL IMMUNE DEFICIENCY; LYMPHOID CELL; MICROENVIRONMENT; NONHUMAN; PLASMA CELL; SHORT SURVEY; SPLEEN; THROMBOCYTOPENIA;

EID: 84892169206     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00494     Document Type: Short Survey

References (31)

1. Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood (2008) 112:999-1004. doi:10.1182/blood-2008-01-131029
2. Leandro MJ, Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol (2011) 25:535-48. doi:10.1016/j.berh.2011.10.005
3. Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 8:505-14. doi:10.1038/nrneph.2012.141
4. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 369:417-27. doi:10.1056/NEJMoa1213277
5. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 174:817-26.
6. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol (2007) 179:3351-61.
7. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 199:1659-69. doi:10.1084/jem.20040119
8. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol (2005) 174:4389-99.
9. Baumjohann D, Preite S, Reboldi A, Ronchi F, Ansel KM, Lanzavecchia A, et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity (2013) 38:596-605. doi:10.1016/j.immuni.2012.11.020
10. Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum (2010) 62:2443-57. doi:10.1002/art.27515
11. Ahuja A, Teichmann LL, Wang H, Dunn R, Kehry MR, Shlomchik MJ. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in lupus. J Immunol (2011) 187:3888-94. doi:10.4049/jimmunol.1101629
12. Mei HE, Frolich D, Giesecke C, Loddenkemper C, Reiter K, Schmidt S, et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood (2010) 116:5181-90. doi:10.1182/blood-2010-01-266536
13. Mahévas M, Patin P, Huetz F, Descatoire M, Cagnard N, Bole-Feysot C, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest (2013) 123:432-42. doi:10.1172/JCI65689
14. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood (2009) 113:6511-21. doi:10.1182/blood-2009-01-129155
15. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest (1998) 102:1393-402. doi:10.1172/JCI4238
16. Daridon C, Loddenkemper C, Spieckermann S, Kuhl AA, Salama A, Burmester GR, et al. Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. Blood (2012) 120:5021-31. doi:10.1182/blood-2012-04-424648
17. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 6:741-50. doi:10.1038/nri1886
18. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med (2004) 199:1577-84. doi:10.1084/jem.20040168
19. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity (1998) 8:363-72. doi:10.1016/S1074-7613(00)80541-5
20. Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A (2008) 105:4802-7. doi:10.1073/pnas.0800555105
21. Tangye SG. Staying alive: regulation of plasma cell survival. Trends Immunol (2011) 32:595-602. doi:10.1016/j.it.2011.09.001
22. Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev (2013) 251:177-88. doi:10.1111/imr.12011
23. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol (2009) 9:491-502. doi:10.1038/nri2572
24. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol (2008) 180:3655-9.
25. Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol (2012) 188:497-503. doi:10.4049/jimmunol.1102321
26. Joo H, Coquery C, Xue Y, Gayet I, Dillon SR, Punaro M, et al. Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation. J Exp Med (2012) 209:1335-48. doi:10.1084/jem.20111644
27. Ellyard JI, Avery DT, Mackay CR, Tangye SG. Contribution of stromal cells to the migration, function and retention of plasma cells in human spleen: potential roles of CXCL12, IL-6 and CD54. Eur J Immunol (2005) 35:699-708. doi:10.1002/eji.200425442
28. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest (2003) 112:286-97. doi:10.1172/JCI18025
29. Rodriguez Gomez M, Talke Y, Goebel N, Hermann F, Reich B, Mack M. Basophils support the survival of plasma cells in mice. J Immunol (2010) 185:7180-5. doi:10.4049/jimmunol.1002319
30. Withers DR, Fiorini C, Fischer RT, Ettinger R, Lipsky PE, Grammer AC. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood (2007) 109:4856-64. doi:10.1182/blood-2006-08-043414
31. Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med (2013) 368:1528-35. doi:10.1056/NEJMct1207259